Telomere length analysis provides unique insights into the pathogenesis of MDS and AML and is associated with a worse overall survival in MDS but not AML

被引：0
|
作者：
Williams, J. [1 ]
Knapper, S. [1 ]
Hills, R. [1 ]
Pepper, C. [1 ]
Fegan, C. [1 ]
Baird, D. [1 ]
机构：
[1] Sch Med, Inst Canc & Genet, CLL Res Grp, Cardiff, S Glam, Wales
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 169卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
217
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [1] CYTOGENETIC EVOLUTION IN MDS: IS IT PREDICTIVE OF OVERALL SURVIVAL AND RISK OF MDS/AML EVOLUTION?
    Bernasconi, P.
    Klersy, C.
    Boni, M.
    Dambruoso, I.
    Cavigliano, P. M.
    Zappatore, R.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Calvello, C.
    Caresana, M.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 104 - 104
  • [2] Overall survival in TP53-mutated AML and MDS
    Puzo, Christian J.
    Hager, Karl M.
    Rinder, Henry M.
    Weinberg, Olga K.
    Siddon, Alexa J.
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5359 - 5369
  • [3] Telomere length is an independent prognostic marker in MDS but not in de novo AML
    Williams, Jenna
    Heppel, Nicole H.
    Britt-Compton, Bethan
    Grimstead, Julia W.
    Jones, Rhiannon E.
    Tauro, Sudhir
    Bowen, David T.
    Knapper, Steven
    Groves, Michael
    Hills, Robert K.
    Pepper, Chris
    Baird, Duncan M.
    Fegan, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (02) : 240 - 249
  • [4] TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS
    Puzo, Christian
    Hager, Karl
    Rinder, Henry
    Weinberg, Olga
    Siddon, Alexa
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1468 - S1470
  • [5] AZACITIDINE TREATMENT OF HIGH RISK MDS AND AML, ANALYSIS OF LONG RESPONDING PATIENTS AND PROGNOSTIC FACTORS OF OVERALL SURVIVAL, CZECH MDS GROUP EXPERIENCE
    Jonasova, A.
    Cermak, J.
    Cervinek, L.
    Belohlavkova, P.
    Cerna, O.
    Kacmarova, K.
    Janousova, E.
    LEUKEMIA RESEARCH, 2015, 39 : S53 - S53
  • [6] Impact of Mutated Genes By Next Generation Sequencing on Overall Survival in a Cohort of Peruvian Patients with AML/MDS
    Carrasco-Yalan, Antonio A.
    Pinto, Joseph A.
    Valdes-Gomez, Jorge J.
    Saldarriaga, Tatiana
    Morales-Coloma, Melissa
    Pando-Mayta, John W.
    Cuyutupac-Barja, Marylin
    Arias-Arana, Paloma
    Vigo-Ames, Natalia I.
    Arbizu-Chipana, Angela
    Quintana, Shirley
    Doimi, Franco
    Samanez-Figari, Cesar
    Haro-Vargas, Juan
    Castillo-Aguirre, Jorge
    Lopez, Marco
    Enriquez, Daniel J.
    BLOOD, 2020, 136
  • [7] WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients
    Aydin, Semra
    Schmitz, Jennifer
    Dellacasa, Chiara M.
    Dogliotti, Irene
    Giaccone, Luisa
    Busca, Alessandro
    CANCERS, 2024, 16 (17)
  • [8] AML and MDS treated with nonmyeloablative stem cell transplantation: Overall and progression free survival comparable to myeloablative transplantation.
    Alyea, EP
    Kim, HT
    Cutler, C
    Ho, V
    Lee, SJ
    Parik, B
    Windawi, S
    DeAngelo, D
    Stone, RM
    Ritz, J
    Antin, JH
    Soiffer, RJ
    BLOOD, 2003, 102 (11) : 79A - 79A
  • [9] Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
    Sallman, David A.
    Al Ali, Najla
    Yun, Seongseok
    Padron, Eric
    Song, Jinming
    Hussaini, Mohammad Omar
    Talati, Chetasi
    Sweet, Kendra L.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2018, 132
  • [10] Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Ching, Keith A.
    Huang, Donghui
    Wang, Kai
    Ozeck, Mark
    Lira, Paul
    Gao, Jingjin
    Bienkowska, Jadwiga
    Rejto, Paul
    Hardwick, James
    O'Brien, Thomas
    Chan, Geoffrey
    CANCER RESEARCH, 2018, 78 (13)
12345